Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model without human clinical data
PubMed 11595448 · doi:10.1016/s0928-4257(01)00036-5
What was done
Researchers evaluated whether intrarectal cysteamine induces colon lesions in rats and tested the cytoprotective effects of gastric pentadecapeptide BPC 157 compared with standard antiulcer and anti-inflammatory agents. Colon lesions were induced via intrarectal cysteamine (200 or 400 mg/kg), with diluted HCl (pH 3.8) as an irritant control. Agents including BPC 157 (10 µg/kg or 10 ng/kg), ranitidine (10 mg/kg), cimetidine (50 mg/kg), omeprazole (10 mg/kg), atropine (10 mg/kg), methylprednisolone (1 mg/kg), and sulphasalazine (50 mg/kg) were administered intraperitoneally, intragastrically, or intrarectally simultaneously with intrarectal cysteamine, or 1 hour prior to subcutaneous cysteamine (400 mg/kg) for duodenal ulcer assessment. Outcomes were evaluated between 30 minutes and 72 hours.
What was found
Intrarectal cysteamine produced transmural colon lesions with serosal involvement. BPC 157 (10 µg/kg or 10 ng/kg) administered via all three routes inhibited colon lesions across all assessed time points (30 min to 72 h) after 200 or 400 mg/kg cysteamine. Standard antiulcer agents, methylprednisolone, and intrarectal sulphasalazine attenuated colon lesions assessed at 30 minutes following 200 mg/kg cysteamine. Duodenal lesions assessed 24 hours after subcutaneous cysteamine were attenuated by all agents given intraperitoneally 1 hour prior, except sulphasalazine. The abstract provides no numerical measurements, lesion scores, or statistical values.
Why it matters
This study demonstrates that cysteamine creates colonic injury in addition to duodenal ulceration in rodents, and that BPC 157 provides mucosal cytoprotection across both the upper and lower gastrointestinal tract in this experimental model.
Limits
The study was conducted entirely in rats and cannot be directly translated to human efficacy. The abstract reports no sample sizes (n), quantitative lesion metrics, variance data, or p-values.
Cited by
- supports In mouse studies, administration of BPC-157 demonstrated protection deeper in the gastrointestinal tract against an offending agent introduced into the gut.